Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 19/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5398612 | 1.00 | CCR5 (0.74) | CCR5 | |
| SCHEMBL5400496 | 0.94 | CCR5 (0.74) | CCR5 | |
| SCHEMBL5400492 | 0.94 | CCR5 (0.74) | CCR5 | |
| SCHEMBL5402029 | 0.91 | CCR5 (0.69) | CCR5 | |
| SCHEMBL5402024 | 0.91 | CCR5 (0.69) | CCR5 | |
| SCHEMBL5391548 | 0.86 | CCR5 (0.81) | CCR5 | |
| SCHEMBL5391544 | 0.86 | CCR5 (0.81) | CCR5 | |
| SCHEMBL5398642 | 0.85 | CCR5 (0.71) | CCR5 | |
| SCHEMBL5398634 | 0.85 | CCR5 (0.71) | CCR5 | |
| SCHEMBL5761711 | 0.85 | CCR5 (0.73) | CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007505951-A | — | — | 2007-03-15 | — | — | JP | claimed |
| EP-1633737-A1 | QUINOLYL AMIDE DERIVATIVES AS CCR-5 ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-03-15 | — | — | EP | claimed |
| US-20050020605-A1 | Quinolyl amide derivatives as CCR-5 antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-01-27 | — | — | US | claimed |
| WO-2004113323-A1 | QUINOLYL AMIDE DERIVATIVES AS CCR-5 ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-12-29 | — | — | WO | claimed |
| EP-1633737-A1 | QUINOLYL AMIDE DERIVATIVES AS CCR-5 ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-03-15 | — | — | EP | disclosed |
| US-20050020605-A1 | Quinolyl amide derivatives as CCR-5 antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-01-27 | — | — | US | disclosed |
| WO-2004113323-A1 | QUINOLYL AMIDE DERIVATIVES AS CCR-5 ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020605-A1 | Quinolyl amide derivatives as CCR-5 antagonists | CCRL2, CCR5, CCR1 | CCR5 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.